Business Context and Reporting Period
This Form 8-K was filed by Ovid Therapeutics Inc. on December 23, 2019, reporting events that occurred on December 18, 2019. The filing details compensation decisions made by the Compensation Committee regarding the company's named executive officers and principal financial officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Executive Compensation Details
| Executive | 2019 Cash Bonus | 2020 Base Salary | 2020 Bonus Target | 2020 Option Grant |
|---|---|---|---|---|
| Jeremy M. Levin (CEO) | $265,225 | $560,000 | 50% | 600,000 shares |
| Amit Rakhit (President & CMO) | $199,167 | $500,000 | 40% | 200,000 shares |
| Timothy Daly (PFO & EVP Finance) | $111,357 | $385,000 | 40% | 125,000 shares |
Equity Terms: Options have an exercise price of $4.42 per share (closing price on Dec 18, 2019), a 10-year term, and vest over 4 years (25% after one year, remainder monthly).
Material Changes
- Severance Adjustment: Timothy Daly's severance benefits were modified. Upon termination within 12 months of a change in control, he is now entitled to 12 months of base salary payable over 12 months.
- Compensation Increases: Base salaries for all three executives are effective January 1, 2020.
Outlook, Risks, and Contingencies
The filing notes that the company anticipates entering into an amended and restated employment agreement with Timothy Daly, which will be filed in the 2019 Form 10-K. No specific business outlook, risks, or unusual items regarding operations were disclosed in this report.
Investor Verification Checklist
- Verify the final terms of the amended employment agreement for Timothy Daly in the upcoming Form 10-K.
- Confirm the impact of the new equity grants on total share count and potential dilution.
- Review the 2019 Form 10-Q for prior severance terms to fully understand the magnitude of the change for Mr. Daly.